The PE Ratio as of July 2024 (TTM) for Exelixis, Inc. (EXEL) is 35.98

According to Exelixis, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 35.98. This represents a change of -91.75% compared to the average of 436.01 of the last 4 quarters.

Exelixis, Inc. (EXEL) Historical PE Ratio (quarterly & annually)

How has EXEL PE Ratio performed in the past?

The mean historical PE Ratio of Exelixis, Inc. over the last ten years is 16.64. The current 35.98 PE Ratio has changed 21.52% with respect to the historical average. Over the past ten years (40 quarters), EXEL's PE Ratio was at its highest in in the September 2023 quarter at 1.66K. The PE Ratio was at its lowest in in the September 2016 quarter at -72.63.

Exelixis, Inc. (EXEL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Exelixis, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Exelixis, Inc. (EXEL) Average PE Ratio

How has EXEL PE Ratio performed in the past?

The current PE Ratio of Exelixis, Inc. (EXEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Exelixis, Inc. (EXEL) PE Ratio vs. Peers

How is EXEL’s PE Ratio compared to its peers?

Exelixis, Inc.’s PE Ratio is less than TG Therapeutics, Inc. (72.99), greater than Viking Therapeutics, Inc. (-75.29), greater than Madrigal Pharmaceuticals, Inc. (-12.81), greater than BioXcel Therapeutics, Inc. (-0.23), less than BioMarin Pharmaceutical Inc. (77.76), greater than Seagen Inc. (-57.36), greater than Alnylam Pharmaceuticals, Inc. (-89.20), greater than Halozyme Therapeutics, Inc. (22.39), greater than X4 Pharmaceuticals, Inc. (-1.34), greater than PDS Biotechnology Corporation (-3.08), greater than PTC Therapeutics, Inc. (-4.50), greater than Reata Pharmaceuticals, Inc. (-89.36), greater than Intercept Pharmaceuticals, Inc. (-13.55), less than Krystal Biotech, Inc. (105.76), greater than Kodiak Sciences Inc. (-0.73), less than Sarepta Therapeutics, Inc. (802.35), greater than Mirati Therapeutics, Inc. (-5.32),

Build a custom stock screener for Exelixis, Inc. (EXEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exelixis, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Exelixis, Inc. (EXEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Exelixis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.